Ads
related to: glucocerebrosidase treatment protocol for diabetes 1- Provider Site
Empower Your Patients.
No Prescription Needed.
- Explore Stelo
Over 25 years of innovation.
Technology from a company you trust
- Order Stelo
For your practice and bring the
benefit of Stelo to your patients.
- Patient Profiles
Meet Stelo Patients.
Learn who benefits from Stelo.
- Provider Site
info.diatribe.org has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
β-Glucocerebrosidase (also called acid β-glucosidase, D-glucosyl-N-acylsphingosine glucohydrolase, or GCase) is an enzyme with glucosylceramidase activity (EC 3.2.1.45) that cleaves by hydrolysis the β-glycosidic linkage of the chemical glucocerebroside, an intermediate in glycolipid metabolism that is abundant in cell membranes (particularly skin cells). [5]
It is a recombinant DNA-produced analogue of the human enzyme β-glucocerebrosidase. Cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by Genzyme Corporation. It is given intravenously after reconstitution as a treatment for Type 1 and Type 3 [4] Gaucher's disease. It is available in formulations containing 200 or 400 ...
Taliglucerase alfa, sold under the brand name Elelyso among others, is a biopharmaceutical medication developed by Protalix and Pfizer. [3] [4] [full citation needed] The drug, a recombinant glucocerebrosidase used to treat Gaucher's disease, is the first plant-made pharmaceutical to win approval by the U.S. Food and Drug Administration (FDA).
The disease is caused by a defect in the housekeeping gene for lysosomal glucocerebrosidase (also known as beta-glucosidase, EC 3.2.1.45 ) on the first chromosome (1q22). The enzyme is a 55.6- kilodalton , 497- amino acid -long protein that catalyses the breakdown of glucocerebroside, a cell membrane constituent of red and white blood cells .
The study found people with type 2 diabetes who are receiving treatment with GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups compared to those taking DPP-4 drugs ...
Type 1 and 2 diabetes was estimated to cause $10.5 billion in annual medical costs ($875 per month per diabetic) and an additional $4.4 billion in indirect costs ($366 per month per person with diabetes) in the U.S. [138] In the United States $245 billion every year is attributed to diabetes. Individuals diagnosed with diabetes have 2.3 times ...
The first patient was treated using the Edmonton protocol in March 1999. The protocol was first published in the New England Journal of Medicine in July 2000. [1] The NEJM report was exciting for the diabetes field because the seven patients undergoing the Edmonton protocol remained insulin-independent after an average of 12 months. [citation ...
“Yeah,” Clark replies, before adding. “It makes me suffering, too.” To show just how it makes her suffer, Clarks begins to breathe heavily, huffing and puffing as her arms go up and down.
Ads
related to: glucocerebrosidase treatment protocol for diabetes 1info.diatribe.org has been visited by 10K+ users in the past month